Baxter to acquire Archemix's hemophilia program

Baxter International Inc. (NYSE:BAX) will acquire the hemophilia assets of Archemix Corp. (Cambridge, Mass.) for $30 million in cash up front and up to $285 million in potential milestones. The deal i...